Assessment of myocardial function, endothelial function and perFUSION in early and advanced disease stages of Hypertrophic CardioMyopathy: FUSION-HCM
- Conditions
- Enlarged heart muscle disease1002859310007510
- Registration Number
- NL-OMON56339
- Lead Sponsor
- Amsterdam UMC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 100
MYBPC3 mutation carrier
MYH7 mutation carrier
Genotype-negative first degree relative of a MYBPC3 or MYH7 mutation carrier
>=70 years old
Insulin-dependent diabetes mellitus
Pregnancy
Smoking
Claustrophobia
Pacemaker/ICD
Renal insufficiency <30 GFR
Hypertension (systolic >140mmHg or diastolic >90mmHg)
For the genotype negative group, no phenotype group, and mild phenotype group:
the use of blood pressure medication (diuretics, beta-blockers, ACE-inhibitors,
angiotensin II receptor blockers, calcium channel blockers, alpha blockers)
For the HCM phenotype group: when it is unsafe to withhold from blood pressure
medication (as specified above) for two days, as assessed by their own
cardiologist
Left ventricular outflow tract gradient > 50mmHg
Aortic valve disease
Left bundle branch block
(History of) Obstructive coronary artery disease
Chronic atrial fibrillation
Hormone replacement therapy
Second or third-degree AV-block, sick-sinussyndrome, prolonged QT-interval
Asthma and other obstructive pulmonary diseases
Previous adverse reaction to adenosine or dotarem
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method